Last updated: April 27, 2026
What is CLINDESSE and what indication does it cover?
CLINDESSE is the branded, intravaginal clindamycin phosphate product (foam) marketed for bacterial vaginosis (BV) in non-pregnant patients. It is a locally acting antibiotic intended to treat BV by delivering clindamycin directly to the vaginal environment.
What clinical-trial evidence supports CLINDESSE?
CLINDESSE’s clinical evidence is built on development-era BV programs that established efficacy for intravaginal clindamycin phosphate versus placebo and/or comparators, with endpoints focused on BV cure rates at short-term follow-up and persistence/recurrence assessments.
Key endpoints typically used in BV trials for intravaginal clindamycin
Across BV programs for intravaginal clindamycin formulations, trial endpoints commonly include:
- “Clinical cure” at a specified day (often around day 7 to day 21 depending on protocol)
- Microbiological cure via Nugent scoring or equivalent BV diagnostic criteria
- Symptom resolution tracking and safety/tolerability (local irritation, dysbiosis-related effects, GI adverse events, and systemic antibiotic effects)
What do the public sources show about trial scope?
Public regulatory and label documents for CLINDESSE describe the pivotal clinical basis for approval, including the formulation’s efficacy and safety in BV populations. Clinical-trial details that are typically disclosed in the US prescribing information include study design, patient populations, and efficacy outcomes at prespecified timepoints.
What clinical trials are currently ongoing or recently updated for CLINDESSE?
No complete, current, cross-indication “trial update” set can be produced from the information available in this prompt. A precise update requires a specific trial registry pull for “CLINDESSE” (and likely for “clindamycin phosphate intravaginal foam,” the generic formulation name, and sponsor-specific identifiers) plus last-update dates and status changes.
How large is the BV market where CLINDESSE competes?
The BV therapeutic market is driven by:
- High prevalence of BV among reproductive-age women
- Recurrence dynamics that drive repeat treatment
- Treatment switching across antibiotic classes and regimen formats
CLINDESSE competes primarily in:
- Intravaginal antibiotic regimens for BV
- Products that target similar microbiologic outcomes and short-term cure endpoints
Competitive set (format and mechanism)
CLINDESSE’s competitive landscape is typically segmented by local antibiotic vs other modalities:
- Intravaginal clindamycin formulations (brand and generic equivalents where approved)
- Intravaginal metronidazole formulations
- Oral antibiotic options (where used off-label or in comparable guidelines)
- Investigational non-antibiotic approaches (probiotics, microbiome-targeting, biofilm/disruption strategies)
Because CLINDESSE is an established antibiotic product, its commercial trajectory depends on:
- Label positioning (BV treatment scope)
- Pricing and contracting
- Generic and formulary dynamics
- Recurrence-driven demand and adherence to regimen
What is the commercial outlook and projection for CLINDESSE?
A numerical projection requires a defined forecast basis: current sales, channel mix, pricing trajectory, competitor entry, patent or exclusivity status in key geographies, and payer/contract outcomes. This prompt does not provide those required inputs.
Drivers that typically shape CLINDESSE’s trajectory
The following factors usually dominate for an established, locally administered antibiotic for BV:
- Formulary access: preferred status within women’s health and infectious disease formularies
- Generic pressure: pricing compression if equivalents or authorized generics enter
- Utilization patterns: clinician prescribing preferences for intravaginal vs oral regimens
- Adherence: regimen usability impacts real-world completion and perceived effectiveness
- Safety and tolerability: local irritation rates influence switching
What regulatory status and IP/exclusivity conditions matter for forecasting?
Forecasting depends on:
- Remaining exclusivity (where applicable)
- Patent estate expiry timing and potential generic entry risk
- Regulatory jurisdiction (US only vs broader international markets)
- Changes to label or formulation that can reset exclusivity
This prompt does not include the CLINDESSE-specific patent/exclusivity timeline needed for a precise projection.
Key Takeaways
- CLINDESSE is the branded intravaginal clindamycin phosphate product indicated for bacterial vaginosis (BV).
- Its efficacy is supported by development-era BV trials using clinical and microbiologic cure endpoints typical for intravaginal antibiotic regimens.
- A current “clinical trials update” with last-update dates and status changes cannot be completed from the information provided.
- A numeric market forecast and sales projection cannot be produced without CLINDESSE-specific commercial baseline and exclusivity/patent details.
FAQs
-
Is CLINDESSE used for BV treatment only?
Yes. CLINDESSE is marketed for bacterial vaginosis (BV) as an intravaginal clindamycin phosphate regimen.
-
What outcome measures do BV trials use for intravaginal antibiotics?
Trials typically use clinical cure and microbiological cure measures at predefined follow-up timepoints, often with Nugent scoring or equivalent diagnostic criteria.
-
What drives CLINDESSE demand in the market?
BV prevalence, recurrence, and formulary-driven prescribing of intravaginal antibiotic regimens.
-
How does generic competition affect products like CLINDESSE?
It usually compresses pricing and can shift volume depending on formulary positioning and payer contracting.
-
Can a numeric sales forecast be made without exclusivity and current sales data?
A defensible projection requires current sales and a timeline of patent/exclusivity and competitive entry, which are not provided here.
References
[1] CLINDESSE (clindamycin phosphate) prescribing information.
[2] US FDA label database entry for CLINDESSE.
[3] Clinical trial registry records for CLINDESSE and intravaginal clindamycin phosphate (search results and status pages).
